IGEM Therapeutics announces final close of £5 million Series A financing round

New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and  novel IgE-based platform technology IGEM Therapeutics (IGEM or “the Company”), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured an additional £3 million to […]

Read more

UCL Spinout Hazy Features in Forbes

AI spinout Hazy, featured in a recent Forbes list selecting the 15 Machine Learning Companies to Watch in Europe. Hazy made the top 10, for its platform that allows developers and data scientists to share data in a GDPR compliant fashion by automating the data anonymisation process. Founded by two experienced software entrepreneurs in collaboration […]

Read more

David Grimm and Simon Goldman make the GUV Powerlist’s Top 25

Global University venturing today announced its GUV Powerlist Awards, which celebrates the top 100 leaders of university venture funds. The Fund’s two investment directors, David Grimm responsible for investments in the physical sciences space and Simon Goldman who manages investments for the biomedical sciences, both made the 16th place in the publication’s list. Read more from […]

Read more

Orchard Therapeutics announces closing of $225 Million Initial Public Offering

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has today announced closing of its initial public offering of 16,103,572 American Depositary Shares (“ADSs”), each representing an ordinary share at an initial public offering price of $14.00 per share. The gross proceeds from the offering were […]

Read more

Global University Venturing Interviews David Grimm

Global University Venturing editor Thierry Heles, recently interviewed UCLTF investment manager David Grimm to find out more about the uniqueness of the Fund and the role that it plays in supporting technologies arising from UCL’s knowledge base. Formed through a close collaboration between UCLB and Albion Capital, David explains how UCLTF was a long time […]

Read more

Gene therapy developer Orchard Therapeutics proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ. J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow are underwriters. Orchard is developing autologous ex vivo lentiviral gene therapies to treat rare primary immune deficiencies and inherited metabolic disorders. In an April deal with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), […]

Read more

Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

UCLTF funded Orchard Therapeutics, today announced the completion of an oversubscribed $150 million Series C financing. The biotechnology company is based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health. The work of Orchard Therapeutics is dedicated to transforming the lives of patients with […]

Read more

UCL spin-out Hazy adds $1.8 million in seed funding

Funding led by the UCL Technology Fund with participation from Nationwide Building Society, Pentland, Amadeus Capital Partners and AI Seed Hazy, the London-based AI company enabling ethical, effortless and GDPR-compliant data sharing for responsible businesses, has announced an additional $1.8 million seed funding led by UCL Technology Fund, alongside Nationwide Building Society, Pentland, Amadeus Capital […]

Read more